SCHEMBL1263501

SCHEMBL1263501

Cc1ccc(-c2cc(-c3cccc(N)c3N)c(-c3ccc(C)cc3)c(-c3ccc(C)cc3)c2-c2ccc(C)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.39
CD44 P16070 1/20 0.37
NPC1 O15118 5/20 0.36
RAB9A P51151 4/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PARP1 P09874 1/20 0.36
ENPP1 P22413 1/20 0.35
ADORA3 P0DMS8 1/20 0.34
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
MAPT P10636 3/20 0.33
HSD17B10 Q99714 2/20 0.33
GAA P10253 2/20 0.33
CHEK1 O14757 1/20 0.33
WEE1 P30291 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KIT P10721 1/20 0.33
KDR P35968 1/20 0.33
FLT3 P36888 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1838861 0.85 ALDH1A1 (0.50) ADORA2ANPC1RAB9AMEN1KMT2A
SCHEMBL4553387 0.83 CHEK1 (0.41) ADORA2ACD44NPC1RAB9AMEN1
SCHEMBL2602432 0.82 CD44 (0.48) ADORA2ACD44NPC1RAB9AMEN1
SCHEMBL29414657 0.82 CD44 (0.48) ADORA2ACD44NPC1RAB9AMEN1
SCHEMBL28621174 0.81 ALDH1A1 (0.43) ADORA2ACD44NPC1RAB9AMEN1
SCHEMBL28409364 0.80 DRD1 (0.37) ADORA2AALDH1A1HSD17B10
SCHEMBL8397637 0.77 CD44 (0.42) ADORA2ACD44NPC1RAB9AADORA3
SCHEMBL4843094 0.77 ADORA2A (0.50) ADORA2ACD44NPC1RAB9AMEN1
SCHEMBL7164278 0.74 ALDH1A1 (0.42) ADORA2ANPC1RAB9AMEN1KMT2A
Ammonia Solution, Strong SCHEMBL2406827 0.73 MEN1 (0.47) ADORA2ANPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8021811-B2 Photoreceptor and method of making same XEROX CORPORATION (US) 2011-09-20 US disclosed
US-8003288-B2 Self-healing photoreceptor XEROX CORPORATION (US) 2011-08-23 US disclosed
US-7960082-B2 Photoreceptor protective overcoat layer including silicone polyether and method of making same XEROX CORPORATION (US) 2011-06-14 US disclosed
US-7935465-B2 Self lubricating photoreceptor XEROX CORPORATION (US) 2011-05-03 US disclosed
US-7879518-B2 includes substrate, charge generating layer, and charge transport layer having N,N,N'N'-tetra(4-methylphenyl)-(1,1'-biphenyl)-4,4'-diamine charge transport molecule antioxidant selected to match oxidation potential of charge transport molecule such as sterically hindered bis-phenols and dihydroquinones XEROX CORPORATION (US) 2011-02-01 US disclosed
US-20090226828-A1 SELF-HEALING PHOTORECEPTOR XEROX CORPORATION (US) 2009-09-10 US disclosed
US-20090220876-A1 SELF LUBRICATING PHOTORECEPTOR XEROX CORPORATION (US) 2009-09-03 US disclosed
US-20090186287-A1 PHOTORECEPTOR AND METHOD OF MAKING SAME XEROX CORPORATION (US) 2009-07-23 US disclosed
US-20090130575-A1 PHOTORECEPTOR XEROX CORPORATION (US) 2009-05-21 US disclosed
US-20080299474-A1 HIGH QUALITY SUBSTITUTED ARYL DIAMINE AND A PHOTORECEPTOR XEROX CORPORATION (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080299474-A1 HIGH QUALITY SUBSTITUTED ARYL DIAMINE AND A PHOTORECEPTOR NR2E3, XPA, PRPH ADORA2A 560/4885CD44 4802/4885NPC1 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.